» Articles » PMID: 18249232

Metastatic Lymph Node Number in Epithelial Ovarian Carcinoma: Does It Have Any Clinical Significance?

Overview
Journal Gynecol Oncol
Date 2008 Feb 6
PMID 18249232
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To analyze the clinicopathological correlations of metastatic lymph node (LN) numbers in patients with epithelial ovarian carcinoma.

Method: A total of 328 patients with epithelial ovarian carcinoma diagnosed and treated at Hacettepe University Hospital during 1982-2005 were retrospectively reviewed. Patients' age, number of resected lymph nodes, clinical disease stage, preoperative Ca-125 levels, peritoneal cytology, presence of ascites, tumor histology, tumor grade, maximal tumor diameter, cytoreductive success, overall and disease-free survivals were compared with respect to the number of metastatic lymph nodes (< 4 vs. > or = 4).

Results: The mean number of resected lymph nodes was 24.5 and mean number of metastatic lymph nodes was 6.2. About 47.3% (n=155) of the patients had < 4 metastatic lymph nodes and the remaining 52.7% of patients (n=173) had > or = 4 metastatic lymph nodes. Univariate comparison of the two groups relived preoperative Ca-125 values, peritoneal cytology and clinical disease stage to be significantly different among the two groups. However, multivariate analysis revealed a high Ca-125 level (> or = 500 IU/l) to be unique factor significantly different among the groups. Survival analysis also could not find a significant difference with respect to overall and disease-free survival among the groups.

Conclusion: The number of metastatic lymph nodes increases as the preoperative Ca-125 values increase. Other patient characteristics do not have a significant effect on the number of metastatic lymph nodes. Metastatic LN number does not have a prognostic significance in terms of either the overall or the disease-free survival. Prospective series are needed for a definitive conclusion.

Citing Articles

Development and validation of an interpretable model integrating multimodal information for improving ovarian cancer diagnosis.

Xiang H, Xiao Y, Li F, Li C, Liu L, Deng T Nat Commun. 2024; 15(1):2681.

PMID: 38538600 PMC: 10973484. DOI: 10.1038/s41467-024-46700-2.


A Nomogram for Preoperative Prediction of the Risk of Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer.

Xiang H, Yang F, Zheng X, Pan B, Ju M, Xu S Curr Oncol. 2023; 30(3):3289-3300.

PMID: 36975463 PMC: 10047242. DOI: 10.3390/curroncol30030250.


The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer.

Deng T, Huang Q, Wan T, Luo X, Feng Y, Huang H J Gynecol Oncol. 2021; 32(3):e40.

PMID: 33825356 PMC: 8039180. DOI: 10.3802/jgo.2021.32.e40.


Low-grade epithelial ovarian cancer: what a radiologist should know.

Elsherif S, Javadi S, Viswanathan C, Faria S, Bhosale P Br J Radiol. 2019; 92(1095):20180571.

PMID: 30604635 PMC: 6541194. DOI: 10.1259/bjr.20180571.


IL-21-secreting hUCMSCs combined with miR-200c inhibit tumor growth and metastasis via repression of Wnt/β-catenin signaling and epithelial-mesenchymal transition in epithelial ovarian cancer.

Zhang Y, Wang J, Wu D, Li M, Zhao F, Ren M Onco Targets Ther. 2018; 11:2037-2050.

PMID: 29692616 PMC: 5901132. DOI: 10.2147/OTT.S147855.